Within the context of the theory of immunological tumour surveillance, the immune system is considered to play an important role in the control and elimination of malignant cells. It is now well established that tumour rejection can be mediated by lymphocytes, most notably, CD8 + cytotoxic T lymphocytes (CTLs). Consequently, many immunotherapy approaches have been developed to enhance the immune response to tumours by directly activating tumour-specific CTLs. Since immune recognition by CTLs requires the presentation of processed peptides in association with major histocompatibility complex (MHC) class I molecules, the success of these cancer vaccination strategies is dependent on the ability of the malignant cells to endogenously process and present target epitopes on their cell surface. However, malignant transformation is frequently associated with escape of tumour cells from immune recognition. Defects in the endogenous processing function may result in a down-regulated presentation of specific antigens in the context of surface MHC class I molecules on tumour cells (Marincola et al, 1994a; Ferrone and Marincola, 1995; Hicklin et al, 1999) and, thus, in resistance to CTL-mediated immune recognition (Darrow et al, 1989; Restifo et al, 1993; Rivoltini et al, 1995; Seliger et al, 1997) . Three different types of antigen processing and/or presentation defects in tumour cells have been documented (reviewed by Khanna, 1998) . Firstly, loss of surface MHC class I expression, caused by structural alterations or dysregulation of the MHC class I molecules, probably represents one of the most important strategies used by tumour cells to evade CTL-mediated recognition. A second immune escape mechanism involves abnormalities in processing of endogenous antigens. For example, a down-regulated expression of LMP2 and LMP7, two subunits of the multicatalytic proteasome complex, blocks the generation of peptide epitopes. Finally, complete deletion of coding sequences or point mutations in peptide transporter genes resulting in loss of TAP-1 and TAP-2 expression inhibits the transport of peptide epitopes from the cytoplasmic compartment into the endoplasmic reticulum. Tumour cells can exhibit either one or a combination of these defects to avoid recognition by CTLs. Since all these immune escape mechanisms will impair the effectiveness of CTL-based immunotherapy approaches, it is highly desirable to establish the antigen-presenting capacities of a given tumour before setting out to develop such a therapy.
Immunohistology and fluorescence-activated cell sorting (FACS) analysis, two assays based on antibody binding, have been widely used to analyse the presence of MHC class I molecules on tumour cells (Garrido et al, 1993; Marincola et al, 1994b) . However, drawbacks of these assays are the restricted sensitivity and the fact that only expression of MHC class I molecules is measured rather than the capacity of the tumour cells to process and present endogenous antigens. Specific lysis by high-affinity CTLs can be induced by only a small number (< 10-100) of ligands per target (Demotz et al, 1990; Harding and Unanue, 1990;  Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes DCJ Spierings, E Agsteribbe*, J Wilschut and A Huckriede Laboratory of Molecular Virology, Department of Medical Microbiology, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands Summary Immunotherapy of tumours by induction of tumour-specific cytotoxic T-lymphocytes (CTLs) will only be effective for tumours with a functional antigen processing and presentation machinery. However, many tumours are known to down-regulate expression of major histocompatibility complex (MHC) class I molecules and/or to impair antigen processing. It is therefore desirable to evaluate the ability of a given tumour to present antigenic epitopes before developing an immunotherapy protocol. In this study we have used influenza virus as a tool to determine the antigen-presenting capacities of the murine neuroblastoma C1300 cell line NB41A3, a frequently used model for human neuroblastoma. Immunofluorescence analyses revealed low and moderate expression of MHC class I molecules D d and K k respectively. Nevertheless, infected NB41A3 cells were lysed efficiently by influenza-specific CTLs. These results demonstrate that all steps of the antigenprocessing pathway function properly in the NB tumour cells, and that the limited MHC class I expression suffices for efficient recognition by CTLs. In addition, lysis of the NB tumour cells shows that the cells are susceptible to CTL-induced apoptosis, a pathway that is often impaired in tumour cells. These characteristics make neuroblastoma a suitable target for immunotherapy. The presented assay allows evaluation of various immunological properties of tumour cells and, thus, represents a valuable tool to assess whether a given tumour will be susceptible to immunotherapy or not. © 2000 Cancer Research Campaign Keywords: tumour; antigen presentation; immunotherapy; influenza virus Christinck et al, 1991; Sykulev et al, 1996) . Consequently, a poor or negligible expression of MHC class I molecules as determined by immunohistology or FACS analysis, does not necessarily indicate complete absence of recognition by CTLs.
The present study describes a method to directly determine the antigen-presenting properties of (tumour) cells using influenza virus as a tool. In this approach, tumour cells which, after virus infection, process and present viral antigens properly, will be recognized and lysed by influenza-specific CTLs while absence of lysis indicates the presence of defects in the antigen-processing machinery. To evaluate the potential of this influenza virus-based method we used the murine neuroblastoma (NB) C1300, a wellestablished model for human disease (Ziegler et al, 1997) . NBs are poorly immunogenic and characterized by low expression of MHC class I antigens (Lampson et al, 1983) . Nevertheless, we observed that influenza-infected NB41A3 cells are efficiently lysed by influenza-specific CTLs. This result indicates that early steps in antigen processing are not impaired in NB41A3 cells, that a small number of antigen-MHC class I complexes is sufficient to allow recognition by specific CTLs, and that NB tumour cells are vulnerable to CTL-mediated cytotoxicity.
MATERIALS AND METHODS

Cell lines
The murine C1300 neuroblastoma cell line, clone NB41A3,
, and the mastocytoma cell line P815 (H-2D d ) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in RPMI-1640 medium (Gibco-BRL, Breda, The Netherlands) supplemented with 10% heat-inactivated fetal calf serum (FCS; PAA Laboratories GmbH, Austria) and 1 mM glutamine.
Antibodies
Monoclonal antibody (mAb) reactive with mouse MHC class I H-2K k (mouse IgG2a) was purchased from ATCC (HB-16 16-1-11N hybridoma cell line). mAb to MHC class I H-2D d (mouse IgG2a, MCA 1055) was obtained from Serotec (Apeldoorn, The Netherlands). Fluorescein isothiocyanate (FITC)-conjugated goat anti-(mouse IgG) was purchased from Nordic Immunological Laboratories (Tilburg, The Netherlands).
Treatment of cells with interferon α
NB41A3 cells were cultured in fresh medium containing 750 U ml -1 murine recombinant interferon γ (IFN-γ; Gibco-BRL). The cells were incubated for 3 days and washed in medium before use. 
Induction of CTLs
Six-to 8-week-old female A/J mice (H-2D d K k ) were obtained from Harlan (Zeist, The Netherlands) and maintained in our animal facilities. For sensitization in vivo, mice were given intraperitoneal (i.p.) injections of 0.1 ml allantoic fluid containing influenza A/Port Chalmers/1/73 (H3N2) (10 7 infectious units ml -1 ) kindly provided by Solvay Pharmaceuticals (Weesp, The Netherlands). Two weeks later, splenocytes from the immunized mice were re-stimulated in vitro for 5 days with influenza-infected syngeneic spleen cells or with influenza-infected NB41A3 cells at an effector:stimulator ratio of 5:1. Spleen cells were collected and assayed for cytotoxic activity against influenza virus in a 4-h 51 Cr-release assay.
Cytotoxicity assays
One million influenza-infected and non-infected NB41A3 cells were labelled with 20µCi Na 2 51 CrO 4 (Amersham, UK) for 1 h. These labelled target cells (10 4 in 0.05 ml medium per well) were then cocultured with serial dilutions of effector cells (0.1 ml per well) in round-bottomed microtiter wells. After 4 h incubation at 37°C, 0.1 ml supernatant was collected for γ-radiation counting. Medium with or without 0.5% Triton X-100 (Sigma) was used for the determination of maximal release or spontaneous release respectively. The percentage specific lysis was calculated as [(experimental release -spontaneous release)/(maximal releasespontaneous release)]× 100%. Where indicated, cytolytic activity was blocked by including saturating concentrations of anti-MHC I D d or anti-MHC I K k during labelling of target cells with Na 2
51
CrO 4 . Mean radioactivity was determined from triplicate cultures. Influenza virus infection is known to induce IFN-α and IFN-β which in turn can induce up-regulation of MHC class I molecules (Halloran et al, 1989) . We therefore evaluated the effect of acute influenza virus infection on expression of MHC class I molecules by staining NB41A3 cells 2.5 or 6 h post-infection. As shown in Figure 1 , influenza virus infection of NB41A3 cells did not affect the expression of either MHC class I molecule on NB41A3 cells.
RESULTS
Expression of MHC class I molecules
MHC class I-restricted lysis of infected NB41A3 cells by influenza-specific CTLs
To investigate the antigen-presenting capacities, NB41A3 cells were infected with influenza virus A/Port Chalmers/1/73 (H3N2) and their susceptibility to killing by influenza-specific CTLs was determined. Influenza-specific CTLs were generated in A/J mice by i.p. immunization with 10 6 infectious units of Port Chalmers virus. As demonstrated in Figure 2A , virus-infected NB41A3 cells were efficiently lysed by influenza-specific CTLs (58% Cr-release assay. Susceptibility of non-stimulated NB41A3 cells (A) was compared with that of IFN-γ-stimulated NB41A3 cells (B). v, NB41A3 cells; s, influenzainfected NB41A3 cells specific lysis at E:T ratio 30:1). The sensitivity to lysis was increased to 78% when NB41A3 cells were stimulated with IFN-γ for 3 days prior to the 51 Cr-release assay ( Figure 2B ). To identify possible H-2 restriction elements, the ability of appropriate antibodies to inhibit lysis of influenza-infected NB41A3 cells by influenza-specific CTLs was determined. As demonstrated in Figure 3 , lysis of infected NB41A3 cells was partially inhibited by antibodies against MHC I D d , but not by antibodies against K k (48% and 0% inhibition respectively).
In vitro stimulation of influenza-primed CTLs by infected NB41A3 cells
In order to test the ability of NB41A3 cells to stimulate spleen cells in vitro, bulk T cells of mice primed with Port Chalmers virus were incubated with virus-infected NB41A3 cells for 5 days. Cytotoxic activity of these T cells against infected targets was compared to that of T cells stimulated by influenza-infected spleen cells. As shown in Figure 4 , infected NB41A3 cells could efficiently stimulate influenza-primed CTLs in vitro. Both splenocyteand NB41A3-stimulated CTLs showed a similar level of specific lysis of influenza-infected target cells. Interestingly, lysis of noninfected targets being rather high for splenocyte-stimulated CTLs in this experiment ( Figure 4A ), was considerably lower when restimulation was performed with infected NB41A3 cells ( Figure  4B ).
DISCUSSION
In the present study, we used influenza virus as a tool to determine the antigen presenting capacities of NB tumour cells. Clearly, influenza-infected NB41A3 cells can be recognized and lysed in vitro by influenza-specific CTLs only if the cells process and present viral antigens properly. Thus, the influenza assay measures three important steps in the MHC class I processing pathway, e.g. (i) processing of influenza-derived proteins to presentable peptides; (ii) transport of these peptides from the cell cytosol to the ER by TAP-1/TAP-2; (iii) presentation of the peptides in context of MHC class I molecules on the cell surface. Therefore, this functional assay evaluates not only the level of cell surface expression of MHC class I molecules, but also defects in the function of the proteasome subunits LMP2/LMP7 and the peptide-transporters TAP-1/TAP-2. In addition, the influenza virus-based assay also measures the susceptibility of tumour cells for lysis by CTLs. T cells can cause the destruction of target cells by two mechanisms, one involving the death-signalling receptor CD95 (also called APO-1 or Fas) and the other involving the perforin-granzyme system. Both mechanisms eventually activate the caspase cascade leading to apoptosis (Froelich et al, 1996; Nagata, 1997) . According to Strand and Galle (1998) , an impaired anti-tumour immune response can be caused by reduced tumour-cell responsiveness to stimulation of CD95. In fact, many cancer cells are relatively resistant to CD95-mediated apoptosis because of loss of CD95 (no triggering of Tcell-induced apoptosis) or defects in the CD95 signalling pathway (no response to T-cell-induced apoptosis). Furthermore, many tumour cells overexpress apoptosis inhibitors such as Bcl-2 and Bcl-2 family members, which abrogate not only CD95-induced but also perforin-mediated apoptosis. The presented influenza virus-based assay can be used to evaluate the presence of such apoptosis-inhibiting mechanisms and can help to demonstrate susceptibility of tumour cells to CTL-mediated lysis in general.
To test the influenza virus-based method we used the murine neuroblastoma (NB) C1300, a well-established model for human disease (Ziegler et al, 1997) . NB is a typical poorly immunogenic tumour and incapable to elicit a specific immune response by virtue of a low MHC class I expression and its deficiency in MHC class II, costimulatory and adhesion molecules (Lampson et al, 1983; Main et al, 1985; Zier et al, 1990; Katsanis et al, 1995) . The low expression of MHC class I molecules was confirmed in this study. MHC class I down-regulation in NB cells is probably caused by overexpression of the N-myc oncogene which lowers the expression of the p50 subunit of NF-κB, a transcription factor binding to the enhancer-A element in the MHC class I gene promoter (Bernards et al, 1986; Lenardo et al, 1989; van't Veer et al, 1993) .
In the context of the antigen-presentation assay, influenzainfected NB cells were efficiently recognized and lysed by influenza-specific CTLs despite the low expression of the relevant MHC class I molecules. Lysis was not due to MHC class I upregulation by virus infection since infected NB cells showed no differences in expression of these molecules in comparison with non-infected NB cells. Although an up-regulated expression of MHC class I molecules by IFN-γ stimulation slightly increased the sensitivity of NB tumour cells to lysis, the limited number of MHC class I molecules expressed under physiological conditions appeared to be sufficient for efficient recognition by CTLs.
CTL-mediated killing of influenza-infected NB cells appeared to be restricted by H-2D d as shown by the fact that antibodies to H-2D d but not antibodies to H-2K k could reduce lysis. Interestingly, although viral nucleoproteins (NP) are often immunodominant targets for CTLs (Townsend et al, 1984; Yewdell et al, 1985) , a conserved H-2K k -binding epitope (AA50-57: SDYE-GRLI), derived from influenza NP (Parker and Gould, 1996) does obviously not play an important role in the killing of infected NB cells. Limited importance of an immunodominant NP-derived epitope was found earlier for peptide TYQRTALV (AA147-155) of influenza A/Puerto Rico/8/34 (H1N1). CTLs restimulated with influenza-infected cells, thus with a number of epitopes simultaneously, failed to recognize target cells which had been loaded with this NP peptide only (own observations). With respect to lysis of the NB cells, unknown H-2D d -specific epitopes derived from NP, the matrix protein (M), or, perhaps, haemagglutinin (HA) were apparently immunodominant since lysis was restricted by H-2D d . Unfortunately, influenza virus strain A/Port Chalmers/1/73 (H3N2) is poorly characterized as far as H-2-binding epitopes are concerned.
Besides being targets for influenza-specific CTLs, infected NB cells were also capable of stimulating bulk spleen cells in vitro. Stimulated spleen cells from influenza-primed mice, but not from PBS-injected control mice, could efficiently lyse influenzainfected target cells. It might be argued that stimulation was not mediated by the primarily infected NB41A3 cells but by secondarily infected spleen cells. Indeed, infected NB cells used as stimulators will produce virus. However, due to lack of a proper trypsin-like protease, cleavage of the viral haemagglutinin does not take place rendering the produced virus uninfectious (Klenk et al, 1975; Lazarowicz and Choppin, 1975) . Therefore, stimulation of T cells by cells other than the initially infected NB cells can be excluded.
In summary, the present study demonstrates that the poorly immunogenic NB cells: (i) do possess a functional antigenprocessing machinery, (ii) present antigen despite a low surface expression of the relevant MHC class I molecules, and (iii) are susceptible to lysis by activated CTLs. The efficient lysis of NB cells in this assay implies that NBs are suitable targets for immunotherapy if an effective way of immunization can be found to activate NB-specific CTLs. This paper presents a reliable and widely applicable functional assay using the influenza virus as a tool to determine the antigen processing and presenting capacities of tumour cells and to test their susceptibility to lysis by activated CTLs.
